Diagnosis and Management of HER2-Positive Breast Cancer Opportunities to Improve Patient Outcomes

Sponsored by Medical Education Collaborative, Inc (MEC)

ACPE-accredited and produced by North American Center for Continuing Medical Education-Princeton CME

Purpose Statement

This educational activity is designed to educate managed markets physicians and pharmacists, case managers, and practice managers on practical, evidence-based approaches to improve patient outcomes in human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

Target Audience

This activity is designed for managed markets physicians and pharmacists, case managers, and practice managers.

Learning Objectives

After completing this activity, participants should be able to:

Describe the clinical and economic burden of HER2-positive breast cancer and the impact of early classification and management
Outline current and emerging diagnostic measures for breast cancer identification and classification
Summarize the risk/benefit profiles of HER2-positive breast cancer medications, including chemotherapeutic and biologic therapies
Discuss evidence-based approaches to HER2-positive breast cancer diagnosis and management to optimize patient outcomes

Credit Eligibility

To be eligible for documentation of credit, participants must participate in the full educational activity—via read-only or audio-accompanied slides, or accredited articles in PDF format—complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print their documentation of credit.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

Release date: June 12, 2008; Expiration date: June 12, 2009

Estimated time to complete: 1 hour

There is no fee associated with this activity.

Lecture Components

The presentation slides, accredited articles in PDF format, post-test, and evaluation form are available as a click through via the menu at the top of each page of this educational activity.

CME Accreditation

Medical Education Collaborative, Inc (MEC) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

MEC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For questions regarding the ACCME accreditation of this activity, please contact MEC at 866-420-3252

CPE Accreditation

Princeton CME is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (ACPE Provider #452) and complies with the Criteria for Quality and Interpretive Guidelines. This activity is approved for 1 contact hour (0.1 CEU) of continuing pharmacy education (UPN 452-999-08-012-H01-P).

Case Manager Accreditation

This activity is approved for 1 hour of continuing education credit for case managers by the Commission for Case Manager Certification (CCMC).

Grant Support

Supported by an educational grant from Genentech BioOncology.

Participating Faculty

William J. Cardarelli, PharmD
Director of Pharmacy
Atrius Health
Harvard Vanguard Medical Associates
Watertown, Massachusetts

Dawn Holcombe, MBA, FACMPE
Executive Director
Connecticut Oncology Association
President
South Windsor, Connecticut

Ruth O'Regan. MD
Director
Clinical and Translational Breast Cancer Research
Director
Hematology/Oncology Fellowship Program
Associate Professor of Hematology/Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Jeannine McCune, PharmD
Associate Professor
University of Washington
School of Pharmacy
Seattle, Washington

Melanie Ann Prince, MSN, CCM, CMAC, CNA, PAHM
Board of Directors
Case Management Society of America
Adjunct Faculty
Trinity University
Washington, DC

Independent Clinical Reviewer

Ana M. Gonzalez-Angulo, MD, MSc, FACP
Assistant Professor
Breast Medical Oncology and Systems Biology
MD Anderson Cancer Center
University of Texas
Houston, Texas

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of Medical Education Collaborative, Inc (MEC) and NACCME-Princeton CME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of MEC and NACCME-Princeton CME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Gonzalez-Angulo: Grant/Research Support—Abraxis Oncology, Genomic Health, Inc, Novartis Oncology, Roche Diagnostics; Speaker—Lilly Oncology
Ms. Holcombe: Speaker’s Bureau—Pfizer; Speaker/Consultant—Alexlon; Advisory board—Eli Lilly and Company
Dr. McCune: Grant/Research support—PDL Biopharma; Author—Educational Concepts, McGraw Hill; Scientific advisory board—Gateway for Cancer Research
Dr. O’Regan: Speaker—Genentech, Genentech Health; Grant Support—Abraxis BioScience, Inc, sanofi aventis U.S.
Dr. Cardarelli and Ms. Prince disclosed no relevant financial relationships with any commercial interests.

Planning Committee employees of MEC, the accredited provider for this activity; Kristin Dickie, Mary Johnson, Randy Robbin, and John Savage, NACCME-Princeton CME have disclosed that they have no relevant financial relationships with any commercial interest.

MEC and NACCME-Princeton CME require faculty to inform participants whenever off-label/unapproved uses of drugs or devices are discussed in their presentations.

The faculty has disclosed that no off-label/unapproved uses of drugs or devices will be discussed.

Privacy Policy

Medical Education Collaborative, Inc (MEC) protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. MEC and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

MEC and NACCME-Princeton CME maintain physical, electronic and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Publisher’s Note

The opinions expressed in this educational activity are those of the presenters and are not attributable to the sponsor or the publisher, editor, or advisory board of Medical Education Collaborative, Inc (MEC) and NACCME-Princeton CME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Copyright © North American Center for Continuing Medical Education, LLC. All Rights Reserved. Permission for accreditation use granted June 12, 2008 to June 12, 2009 to Medical Education Collaborative, Inc (MEC).